Merck has flip-flopped on its legal strategy around Vioxx and is now settling a large number of the suits for $4.85 billion. Previously, the company indicated it would fight each and every one of them.
The settlement is a bit complex. Each individual case will still be reviewed and it’s not a class-action settlement. Plaintiffs would still have the burden of proving their case, although just not in a court of law. Interesting strategy.
The settlement is a bit complex. Each individual case will still be reviewed and it’s not a class-action settlement. Plaintiffs would still have the burden of proving their case, although just not in a court of law. Interesting strategy.